# Exploring the Trajectory of Swallowing Within Psychomotor Development in Spinal Muscular Atrophy: Moving Toward Integrated Care

**Authors:** Sofia Gandolfi, Claudia Dosi, Stefano Parravicini, Maria Teresa Arnoldi, Riccardo Zanin, Sofia Biagi, Livia Rinaldi, Riccardo Masson

PMC · DOI: 10.3390/audiolres15050131 · Audiology Research · 2025-10-07

## TL;DR

This study examines swallowing function in children with Spinal Muscular Atrophy type 1 over one year, finding that swallowing remains stable despite motor improvements from treatment.

## Contribution

The study provides longitudinal insights into swallowing in SMA type 1 patients treated with disease-modifying therapies, emphasizing the need for integrated assessments.

## Key findings

- Swallowing function remained stable over one year despite motor improvements.
- Swallowing scales showed moderate associations with motor and cognitive scores.
- No significant changes in swallowing were observed across subgroups.

## Abstract

Background: Spinal Muscular Atrophy type 1 (SMA type 1) is a genetic neuromuscular disease that typically presents before 6 months of age and is characterized by profound hypotonia, progressive muscle weakness, and early involvement of respiratory and bulbar musculature. Swallowing impairment (dysphagia) is a hallmark of SMA type 1 and significantly contributes to morbidity. Despite the documented benefits of disease-modifying therapies (DMTs) in terms of enhanced survival and motor outcomes, their impact on swallowing remains understudied. Aim: This study aims to longitudinally characterize swallowing function in children with SMA type 1 treated with DMTs, while contextualizing these findings in relation to the patients’ current motor abilities and cognitive performance. Materials and Methods: A single-center, longitudinal, observational study was conducted at IRCCS Besta, Milan, Italy, from 2021 to 2025. Swallowing function was evaluated using four validated scales (MAS, OrSAT, FILS, and p-FOIS), while motor and cognitive functions were assessed using CHOP-INTEND and age-appropriate cognitive tests (DQ/IQ). Patients were stratified by baseline swallowing status, pharmacological therapy, and age at DMT administration. Non-parametric statistical tests were applied. Results: No statistically significant changes in swallowing function were observed over one year in the overall cohort or its subgroups, despite significant improvements in motor function. MAS/e, FILS, and p-FOIS showed moderate associations with CHOP-INTEND and DQ/IQ scores. Conclusions: Swallowing function in children with SMA type 1 remained largely stable, while motor function significantly improved over one year, regardless of baseline swallowing status, DMT type, and age at administration. These findings underscore the need for standardized, longitudinal assessments of swallowing, motor, and cognitive functions in the management of SMA type 1.

## Linked entities

- **Diseases:** Spinal Muscular Atrophy type 1 (MONDO:0009669), SMA type 1 (MONDO:0009669)

## Full-text entities

- **Genes:** DDIT3 (DNA damage inducible transcript 3) [NCBI Gene 1649] {aka AltDDIT3, C/EBPzeta, CEBPZ, CHOP, CHOP-10, CHOP10}
- **Diseases:** genetic neuromuscular disease (MESH:D009468), Swallowing impairment (MESH:D003680), muscle weakness (MESH:D018908), SMA type 1 (MESH:D014897), Spinal Muscular Atrophy (MESH:D009134), hypotonia (MESH:D009123)
- **Chemicals:** DMT (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12561291/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12561291/full.md

## References

49 references — full list in the complete paper: https://tomesphere.com/paper/PMC12561291/full.md

---
Source: https://tomesphere.com/paper/PMC12561291